Decoding Brain Metastasis With Liquid Biopsy: Biomarkers and Technologies in EGFR-Mutant NSCLC

Area of Science:

• Oncology
• Molecular Diagnostics
• Cancer Research

Background:

• Brain metastasis (BM) is a major cause of cancer mortality, particularly in lung cancer.
• Current diagnostic methods like tissue biopsies are often impractical for BM.
• There is a critical need for non-invasive biomarkers for early BM detection.

Purpose of the Study:

• To review the advantages and limitations of liquid biopsy for diagnosing BM.
• To discuss key biomarkers (CTCs, ctDNA, EVs, TEPs) and detection technologies.
• To explore liquid biopsy applications in EGFR-mutant NSCLC and recommend clinical enhancements.

Main Methods:

• Literature review of liquid biopsy techniques and biomarkers for BM.
• Focus on peripheral blood and cerebrospinal fluid (CSF) analysis.
• Examination of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), and tumor-derived platelets (TEPs).

Main Results:

• Liquid biopsy presents a promising non-invasive alternative to traditional methods for BM detection.
• Identified biomarkers like ctDNA and CTCs show potential but face challenges in sensitivity and specificity.
• Liquid biopsy is particularly relevant for EGFR-mutant NSCLC patients with high BM incidence.

Conclusions:

• Liquid biopsy significantly enhances the potential for early detection and management of brain metastasis.
• Further research and technological advancements are needed to overcome current limitations and improve clinical utility.
• Implementing liquid biopsy strategies can improve patient outcomes in oncology, especially for lung cancer.